USA flag logo/image

An Official Website of the United States Government

NEW DRUGS FOR THE TREATMENT OF BREAST CANCER

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
45633
Program Year/Program:
1999 / SBIR
Agency Tracking Number:
1R43CA080472-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
THEREX TECHNOLOGIES, INC.
533 GREAT ARROW AVE BUFFALO, NY 14207
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1999
Title: NEW DRUGS FOR THE TREATMENT OF BREAST CANCER
Agency: HHS
Contract: N/A
Award Amount: $100,378.00
 

Abstract:

Not Available The dispersal of special nuclear material (SNM) from US nuclear weapons has been given high level attention from the executive and legislative branches of government since the early 1990s. The studies and assessments to date have focused on abnormal environments initiated by accidents during normal peacetime military operations. These studies have identified some abnormal environments in which disposal is likely to occur. These environments can be initiated by accident or intentionally by terrorists. Dispersal by intentional means is likely to have the same health and political consequences with respect to public consequences as dispersal by accidental means. Phase I research will develop a methodology to assess intentional actions such that the quantified risk of these actions is comparable with the risk quantified by accepted methods for accidents. The specific objectives are to assess the likelihood and effectiveness of a terrorist attack and support their integration into DTRA's Nuclear Weapon System Safety Assessment.

Principal Investigator:

Joseph A. Dunn

Business Contact:


7166365107
JDUNN @BUFFALO.COM
Small Business Information at Submission:

THEREX TECHNOLOGIES, INC.
533 GREAT ARROW AVE BUFFALO, NY 14207

EIN/Tax ID: 161515836
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No